The high prevalence of TP53 and KRAS mutations underscores the importance of integration of both NGS and MSI testing into clinical practice to guide targeted therapies, personalize treatment strategies, and ultimately improve CRC patient outcomes in Karachi, Pakistan. Here, TP53 is linked to colorectal carcinoma.